⌕

Regeneron Pharmaceuticals (REGN) vs Takeda Pharmaceutical (TAK)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
68
Regeneron Pharmaceuticals, Inc.
$955.47 · $99B · as of last close
Strongest balance sheetHighest qualityFastest grower
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is balance sheet.

#2 FIT
62
Takeda Pharmaceutical Co
$21.43 · $74B · as of last close
Street favoriteCalmest rideBest income
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is analyst sentiment.

REGN edges ahead (68/100 vs TAK 62) under a balanced style, mostly on balance sheet. But TAK wins on analyst sentiment, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorREGNTAK
Overall fit score
weighted for your balanced goal
✓ 68
62
Valuation
Cheaper for what you get
1×
✓ P/E 21 · EV/EBITDA 17.0
P/E trailing
62
P/E — · EV/EBITDA 25.5
fiscal 2026
44
Growth
Revenue & earnings momentum
1×
✓ —
58
—
37
Profitability & quality
Margins & return on capital
1×
✓ Net 29% · ROIC 12%
TTM through Sep 30, 2026
66
Net −3% · ROIC 0%
fiscal 2026
37
Total return
Share-price change with dividends reinvested
1×
5Y +10%/yr
72
✓ 5Y +13%/yr
76
Risk (calm = better)
Volatility & drawdown
1×
β 0.6 · DD −60%
79
✓ β 0.2 · DD −23%
99
Balance sheet†
Debt vs cash cushion
1×
✓ Net debt/EBITDA −1.4×
TTM through Sep 30, 2026
70
Net debt/EBITDA 6.9×
fiscal 2026
9
Dividend & income
Cash paid to you
1×
0.39% yield· B
83
✓ 2.94% yield· D
97
Analyst sentiment
Forward EPS growth (consensus)
1×
Est EPS +4%/yr · 15 analysts
56
✓ Est EPS +57%/yr · 3 analysts
100
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafetyIncome
■ REGN■ TAK
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
REGN−60%0.5532%5Y
TAK−23%0.1719%5Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on balance sheet (score 70). Net debt/EBITDA −1.4× is one of the 5 inputs.

▲ Leads on profitability & quality: Net 29% · ROIC 12% (score 66).

BEAR CASE

▼ Weakest on analyst sentiment: Est EPS +4%/yr · 15 analysts (score 56).

▼ Weakest on risk (calm = better): β 0.6 · DD −60% (score 79).

BULL CASE

▲ Leads on analyst sentiment: Est EPS +57%/yr · 3 analysts (score 100).

▲ Leads on risk (calm = better): β 0.2 · DD −23% (score 99).

BEAR CASE

▼ Weakest on balance sheet (score 9). Net debt/EBITDA 6.9× is one of the 5 inputs.

▼ Weakest on profitability & quality: Net −3% · ROIC 0% (score 37).

WHAT COULD CHANGE THE SCORE
Analyst sentimentCurrently 56/100 (Est EPS +4%/yr · 15 analysts). Taking it to 100 would lift the balanced score by 6 points, the biggest single move available.
GrowthCurrently 58/100 (—). Taking it to 100 would lift the balanced score by 6 points, the next biggest.
Balance sheetCurrently 9/100 (Net debt/EBITDA 6.9×). Taking it to 100 would lift the balanced score by 12 points, the biggest single move available.
GrowthCurrently 37/100 (—). Taking it to 100 would lift the balanced score by 8 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.